Valued at USD 10.07 billion in 2025, the Oral Solid Dosage Contract Manufacturing Market is projected to reach USD 11.02 billion in 2026 and USD 22.62 billion by 2034, growing at a CAGR of 9.4% during the forecast period from 2026 to 2034. Prominent contract development and manufacturing organizations (CDMOs) steering industrial scale-up, formulation development, and global supply chain resilience include Catalent, Inc., Lonza Group, Thermo Fisher Scientific Inc. (Patheon), Recipharm AB, AbbVie Contract Manufacturing, Siegfried Holding AG, Jubilant Pharmova Limited, Evonik Industries AG, Alkem Laboratories, and Dr. Reddy's Laboratories.

The global pharmaceutical landscape is witnessing an accelerating shift toward strategic outsourcing as innovator and generic drug developers seek to optimize capital expenditure and expedite time-to-market. Oral solid dosage forms—specifically tablets and capsules—remain the most preferred patient-friendly drug delivery route globally, commanding significant commercial production volumes.

Formulation Engineering and Advanced Processing Technologies

Contract manufacturers are increasingly tasked with overcoming complex formulation hurdles, particularly when processing poorly soluble active pharmaceutical ingredients. Modern drug molecules often present low aqueous solubility, requiring CDMOs to employ sophisticated particle-size reduction and solid dispersion techniques to ensure target therapeutic profiles.

To achieve precise therapeutic release profiles, CDMOs leverage advanced modified-release technology to produce controlled-release formulations. These specialized dosage forms extend active substance dissolution over specified timeframes, optimizing patient compliance and therapeutic efficacy.

Furthermore, thermal and physical processing relies on robust particle engineering. Modern facilities widely deploy fluid bed granulation systems to combine drying, granulating, and agglomeration within a single unit operation, ensuring uniform mass flow and tablet hardness.

Read More @ https://www.polarismarketresearch.com/industry-analysis/oral-solid-dosage-contract-manufacturing-market

Facility Specialization and Regional Outsources Dynamics

The rising pipeline of oncology therapeutics and targeted treatments has surged demand for containment facilities equipped to handle high-potency compounds. Contract partners are investing heavily in specialized negative-pressure suites and isolator technologies to process highly potent active substances safely without cross-contamination.

These specialized technical capabilities directly drive bioavailability enhancement, ensuring that complex oral solids achieve maximum systemic absorption.

From a regional perspective, the Asia Pacific region leads the global market in both market share and growth velocity. Driven by competitive manufacturing costs, skilled technical workforces, and expanding cGMP-compliant facilities in China and India, Asia Pacific remains the primary manufacturing hub for global oral solid pharmaceuticals.

More Trending Latest Reports By Polaris Market Research:

fastest-growing-markets-to-watch-in-q2-a-sector-by-sector-breakdown

5-things-every-engineer-should-know-about-coolant-distribution-units

metal-stamping-market

spices-seasonings-market

real-time-location-systems-market

embedded-finance-market

middle-east-cybersecurity-market

content-delivery-network-market

fire-safety-equipment-market